Company Encyclopedia
View More
name
EFH
8YY.SG
Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services.
129.59 M
8YY.SGMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking1/4
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE418.50%A
    • Profit Margin-104.74%E
    • Gross Margin28.23%C
  • Growth ScoreA
    • Revenue YoY1007.56%A
    • Net Profit YoY12.56%C
    • Total Assets YoY780.55%A
    • Net Assets YoY146.57%A
  • Cash ScoreB
    • Cash Flow Margin-95.48%D
    • OCF YoY1007.56%A
  • Operating ScoreA
    • Turnover0.93A
  • Debt ScoreE
    • Gearing Ratio76.83%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Embracing Future Holdings Conducts EGM for Key Resolutions

    Embracing Future Holdings Limited, previously Biolidics Ltd., conducted an Extraordinary General Meeting (EGM) in Singapore, where directors and shareholders voted on key resolutions. Chairman Mr. Zhu Hua acted as a proxy for certain shareholders during the voting process. The company currently has a market cap of S$35.51M and an average trading volume of 1,207,206 shares.

    Tip Ranks·
    SG
    8YY
    +6.90%
    Tip Ranks·
    SG
    8YY
    +6.90%

    Biolidics Ltd. Conducts Annual General Meeting with Key Resolutions

    Biolidics Ltd. held its Annual General Meeting (AGM) on April 29, 2024, attended by directors, shareholders, and key personnel. All resolutions were voted on by poll, with the Chairman acting as a proxy for some shareholders. CACS Corporate Advisory Pte. Ltd. assisted with the voting process. The company has a current market cap of S$43.96M and an average trading volume of 1,350,979 shares.

    Tip Ranks·
    SG
    8YY
    +6.90%
    Tip Ranks·
    SG
    8YY
    +6.90%

    Biolidics Ltd. Announces Strategic Initiatives and Business Diversification

    Biolidics Ltd. (SG:8YY) has announced strategic initiatives including issuing new shares and changing its name to Embracing Future Holdings Limited. The company plans to diversify into green energy and AI services, aiming to strengthen its market position and expand operational capabilities. This move may impact stakeholders by broadening the business scope and enhancing the leadership team. Biolidics operates in the biotechnology sector, focusing on innovative medical technology products, with a current market cap of S$35.51M.

    Tip Ranks·
    SG
    8YY
    +6.90%
    Tip Ranks·
    SG
    8YY
    +6.90%

    Biolidics Posts FY Pretax Profit SGD -3.187 Million

    Feb 28 (Reuters) - Biolidics Ltd (BIOL.SI) :* FY PRETAX PROFIT SGD -3.187 MILLION* FY NET INCOME SGD -3.192 MILLION* FY REVENUE SGD 784 THOUSAND Further company coverage: (BIOL.SI)

    Reuters·
    SG
    8YY
    +6.90%
    Reuters·
    SG
    8YY
    +6.90%
    © 2025 Longbridge｜Disclaimer